tuneTypical Dose
5-12 g/day
Fiber Supplement
Inulin
Inulin-type fructans (beta-2,1 linked fructooligosaccharides)
Evidence TierBWADA NOT PROHIBITED
watchEffect Window
Bowel changes often emerge within 2-4 weeks. Metabolic markers often need 6+ weeks.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
Inulin is a prebiotic fiber used to improve bowel function and support metabolic health.
Inulin most consistently helps bowel regularity and stool quality, but its metabolic effects are population-dependent rather than universal. A 2025 randomized trial found improved OGTT glucose handling in overweight and obese adults, while healthy adults did not see the same glycemic benefit, reinforcing the need to match inulin use to the right population and to titrate for GI tolerance.
Fermentable prebiotic fiber that alters colonic fermentation and gut dynamics, with best evidence for bowel regularity and variable cardio-metabolic effects.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- 12 g/day improved stool frequency and constipation burden in functional constipation (PMID:41233756).
- 10 g/day oligofructose-enriched inulin improved glucose/lipid signals in type 2 diabetes (PMID:26819923).
Secondary Outcomes
- Potential modest LDL-C reduction in dyslipidemic crossover protocols (PMID:10395624).
- No consistent appetite/hormonal suppression signal across all studied cohorts (PMID:34589204).
Safety
Contraindications and Interactions
Contraindications
- Severe FODMAP intolerance/IBS-D
- Unstable GI obstruction risk
- Severe active bowel inflammation
Side effects
- Bloating and gas
- Loose stools/diarrhea with dose increases
- Abdominal discomfort
Interactions
- Concurrent high-dose fermentable fibers
- Diabetes medications (monitor glucose)
Avoid if
- Severe fermentation-sensitive history
- Unexplained abdominal pain with red flags
- Active severe bowel inflammation
Evidence
Study-level References
inulin-SRC-001Randomized double-blind crossover trial
Sourceopen_in_newDavidson MH, et al. Effects of dietary inulin on serum lipids. J Nutr. 1999;129(7 Suppl):1474S-1477S. doi:10.1093/jn/129.7.1474S. PMID:10395624.
Population: Hypercholesterolemic adults
Dose protocol: ~18 g/day inulin-containing food equivalent, 6-week crossover
Key findings: Directional LDL-C and total cholesterol reduction versus control phase.
Notes: Small sample, food-formulation confounds, short duration.
Paper content
Directional LDL-C and total cholesterol reduction versus control phase.
inulin-SRC-002Randomized controlled trial
Sourceopen_in_newDehghan P, et al. A combination of prebiotic inulin and oligofructose improve some of cardiovascular disease risk factors in women with type 2 diabetes: a randomized controlled clinical trial. Adv Pharm Bull. 2015;5(4):507-514. doi:10.15171/apb.2015.069. PMID:26819923.
Population: Adults with type 2 diabetes
Dose protocol: 10 g/day for 8 weeks
Key findings: Directional fasting glucose, HbA1c, and selected lipid improvements.
Notes: Cohort-specific and formulation-specific context.
Paper content
Directional fasting glucose, HbA1c, and selected lipid improvements.
inulin-SRC-003Systematic review and meta-analysis.
Sourceopen_in_newde Vries J, et al. Effects of beta-Fructans Fiber on Bowel Function: A Systematic Review and Meta-Analysis. Nutrients. 2019;11(1):91. doi:10.3390/nu11010091. PMID:30621208.
Population: Healthy and symptomatic cohorts.
Dose protocol: Short-chain and long-chain beta-fructans across variable doses
Key findings: Stronger support for bowel-function effects than appetite suppression.
Notes: Heterogeneous formulations and trial designs.
Paper content
Improvement in bowel movement frequency and stool outcomes.
inulin-SRC-004Randomized, double-blind, placebo-controlled trial
Sourceopen_in_newStaudacher HM, et al. Inulin-induced improvements on bowel habit and gut microbiota in adults with functional constipation: findings of a randomized, double-blind, placebo-controlled study. BMC Gastroenterol. 2025;25(1):806. doi:10.1186/s12876-025-04409-6. PMID:41233756.
Population: Adults with functional constipation
Dose protocol: 12 g/day for 4 weeks
Key findings: Improved stool frequency and abdominal symptoms versus control.
Notes: Carry-over management limits interpretation. Early-period effects informed stronger.
Paper content
Improved stool frequency and abdominal symptoms versus control.
inulin-SRC-005Randomized placebo-controlled crossover
Sourceopen_in_newVulevic J, et al. Effect of inulin-type fructans on appetite in patients with type 2 diabetes: a randomised controlled crossover trial. J Nutr Sci. 2021;10:e72. doi:10.1017/jns.2021.70. PMID:34589204.
Population: Adults with type 2 diabetes
Dose protocol: ~16 g/day inulin-type fructans, ~6-week crossover
Key findings: No significant ghrelin/PYY/hunger changes versus control.
Notes: Appetite endpoints were secondary in a metabolically anchored trial.
Paper content
No significant ghrelin/PYY/hunger changes versus control.
inulin-SRC-006Randomized double-blind crossover challenge
Sourceopen_in_newMarteau P, et al. Gastrointestinal tolerance of chicory inulin products. J Am Diet Assoc. 2010;110(6):865-868. doi:10.1016/j.jada.2010.03.025. PMID:20497775.
Population: Healthy adults
Dose protocol: escalating short-term 5 g to higher-dose conditions
Key findings: Dose-related GI symptoms increase. Higher doses had higher symptom burden.
Notes: Healthy population, short-duration challenge design.
Paper content
Dose-related GI symptoms increase; higher doses had higher symptom burden.
inulin-SRC-007Randomized double-blind clinical trial
Sourceopen_in_newLi J, et al. Differential effects of inulin and fructooligosaccharides on gut microbiota composition and glycemic metabolism in overweight or obese and healthy individuals. A randomized, double-blind clinical trial. BMC Med. 2025;23(1):372. doi:10.1186/s12916-025-04189-6. PMID:40598275.
Population: Overweight or obese and healthy adults
Dose protocol: Randomized, double-blind trial comparing inulin, FOS, and placebo for 4 weeks.
Key findings: Inulin improved 1-hour and 2-hour OGTT glucose responses in overweight or obese adults, while healthy adults did not show the same glycemic effect.
Notes: Important modernization because it supports targeted metabolic use rather than a blanket glycemic claim for everyone.
Paper content
Inulin improved OGTT glucose handling in overweight or obese adults, while healthy adults did not show the same glycemic benefit. The trial supports population-specific metabolic use of inulin rather than a universal glucose-lowering claim.
inulin-SRC-008Systematic review and meta-analysis of RCTs.
Sourceopen_in_newTalukdar JR, Cooper M, Lyutvyn L, et al. The effects of inulin-type fructans on cardiovascular disease risk factors: systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr. 2024;119(2):496-510. doi:10.1016/j.ajcnut.2023.10.030. PMID:38309832.
Population: Adults across 55 randomized controlled trials (2,518 participants total).
Dose protocol: Systematic review and meta-analysis of 55 RCTs (2,518 participants) on inulin-type fructans.
Key findings: Modest reductions in LDL cholesterol (-0.14 mmol/L), triglycerides (-0.06 mmol/L), and body weight (approximately 1 kg). Effects stronger with durations over 6 weeks and in overweight populations. Certainty rated low to very low.
Notes: Largest pooled analysis of ITF on cardiovascular risk factors. Confirms directional benefits but underscores modest effect sizes.
Paper content
This systematic review and meta-analysis pooled 55 RCTs with 2,518 participants to evaluate inulin-type fructans (ITF) on cardiovascular disease risk factors. ITF supplementation produced modest reductions in LDL cholesterol (-0.14 mmol/L), triglycerides (-0.06 mmol/L), and body weight (approximately 1 kg). Effects were more pronounced with study durations exceeding 6 weeks and among pre-obese and obese participants. Most other cardiovascular markers showed little to no significant effect. The certainty of evidence was rated low to very low, indicating that while the direction of effect is consistent, the magnitude is small and additional well-designed trials are needed.
inulin-SRC-009Systematic review, meta-analysis, and meta-regression of RCTs.
Sourceopen_in_newReimer RA, Theis S, Zanzer YC. The effects of chicory inulin-type fructans supplementation on weight management outcomes: systematic review, meta-analysis, and meta-regression of randomized controlled trials. Am J Clin Nutr. 2024;120(5):1203-1216. doi:10.1016/j.ajcnut.2024.09.019. PMID:39313030.
Population: Adults across 32 RCTs (1,184 participants for primary body weight outcome).
Dose protocol: Systematic review, meta-analysis, and meta-regression of 32 RCTs (1,184 participants) on chicory inulin-type fructans and weight outcomes.
Key findings: Significant reductions in body weight (approximately 1 kg), BMI (-0.39 kg/m2), fat mass (-0.37 kg), and waist circumference (-1.03 cm). Benefits observed across health statuses.
Notes: Focused specifically on chicory-derived ITF and body composition. Complements the broader CVD meta-analysis with targeted weight management evidence.
Paper content
This systematic review with meta-analysis and meta-regression pooled 32 RCTs examining chicory-derived inulin-type fructans on weight management outcomes. Supplementation significantly reduced body weight by approximately 1 kg, BMI by 0.39 kg/m2, fat mass by 0.37 kg, and waist circumference by 1.03 cm. Benefits were observed across different health statuses, though considerable variability existed in some outcomes. This study complements the broader ITF cardiovascular meta-analysis (PMID 38309832) by focusing specifically on chicory-derived products and body composition endpoints, providing the most targeted weight management evidence for inulin to date.